# Cubist Pharmaceuticals LLC, a trials: 65

ClinicalTrials.gov lists 65 trials with Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA): 65 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/cubist-pharmaceuticals-llc-a-subsidiary-of-merck-and-co-inc-rahway-new

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 65
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 65, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 27, 2015 | NCT02508753 | Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Completed | Healthy | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508753) |
| July 27, 2015 | NCT02508740 | Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Terminated | Renal Impairment | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02508740) |
| March 13, 2015 | NCT02387372 | Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Completed | Critically Ill, Pneumonia | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02387372) |
| January 19, 2015 | NCT02341599 | Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Completed | Healthy Volunteers, Renal Impairment | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02341599) |
| October 28, 2014 | NCT02276482 | Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Skin Diseases, Infectious, Skin Diseases, Bacterial | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02276482) |
| October 17, 2014 | NCT02266706 | Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 1 | Completed | Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02266706) |
| February 25, 2014 | NCT02070757 | Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia, Lung Diseases | 726 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02070757) |
| December 24, 2013 | NCT02019420 | Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Pneumonia | 726 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02019420) |
| August 14, 2013 | NCT01922011 | Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO)... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Acute Hematogenous Osteomyelitis | 149 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01922011) |
| July 17, 2013 | NCT01901341 | The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Terminated | Opioid-Induced Constipation | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01901341) |
| July 17, 2013 | NCT01901328 | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Terminated | Opioid-Induced Constipation | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01901328) |
| July 17, 2013 | NCT01901302 | Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Terminated | Opioid-Induced Constipation | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01901302) |
| May 15, 2013 | NCT01853982 | Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Terminated | Ventilator-Associated Pneumonia (VAP) | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01853982) |
| November 19, 2012 | NCT01728376 | Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 | Completed | Bacteremia | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01728376) |
| October 1, 2012 | NCT01696643 | Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Terminated | Opioid-Induced Constipation | 1,407 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01696643) |
| May 15, 2012 | NCT01598311 | A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Clostridium Difficile Infection | 608 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01598311) |
| May 14, 2012 | NCT01597505 | Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Clostridium Difficile Infection | 606 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01597505) |
| October 4, 2011 | NCT01445678 | Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Complicated Intra-abdominal Infection | 494 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01445678) |
| August 18, 2011 | NCT01419184 | Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 | Completed | Staphylococcal Skin Infections | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01419184) |
| May 2, 2011 | NCT01345929 | Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 | Completed | Complicated Urinary Tract Infection, Pyelonephritis | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01345929) |
| January 12, 2011 | NCT01275755 | Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 | Completed | Constipation | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01275755) |
| September 23, 2010 | NCT01207427 | Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 | Completed | Opioid Induced Constipation | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01207427) |
| August 5, 2010 | NCT01175707 | Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 4 | Terminated | Complicated Skin or Skin Structure Infection | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01175707) |
| June 25, 2010 | NCT01150760 | Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective... | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Observational | Completed | Ileus | 7,050 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01150760) |
| June 22, 2010 | NCT01147640 | Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 2 | Completed | Complicated Intra-abdominal Infection | 122 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01147640) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 2 | 20 |
| Phase 3 | 24 |
| Phase 4 | 10 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 48 |
| Terminated | 17 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Constipation | 12 |
| Pain | 9 |
| Opioid-Induced Constipation | 7 |
| Gram-Positive Bacterial Infections | 6 |
| Ileus | 6 |
| Intestinal Diseases | 5 |
| Bacteremia | 5 |
| Bronchiolitis Obliterans Syndrome | 4 |
| Renal Insufficiency | 4 |
| Clostridium Infections | 3 |
| Diarrhea | 3 |
| Endocarditis | 3 |
| Staphylococcal Infections | 3 |
| Pneumonia | 2 |
| Pneumonia, Ventilator-Associated | 2 |
| Pyelonephritis | 2 |
| Pneumonia, Bacterial | 2 |
| Kidney Failure, Chronic | 2 |
| Soft Tissue Infections | 2 |
| Skin Diseases, Infectious | 2 |
| Endocarditis, Bacterial | 2 |
| Neoplasms | 2 |
| Cellulitis | 1 |
| Blood Loss, Surgical | 1 |
| Cancer Pain | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Litigation law firms in the United States](https://specstream.ai/data/businesses/litigation-law-firms/united-states)
- [Wallpaper installers in the United States](https://specstream.ai/data/businesses/wallpaper-installers/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
- [Propane suppliers in the United States](https://specstream.ai/data/businesses/propane-suppliers/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
